Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor modified T cells (CAR-T) therapy is an emerging immunotherapy against malignancies. However, only limited success was obtained in solid tumors. Polyinosinic-polycytidylic acid (poly I:C), ligand of TLR3, mediates innate immune and adaptive immune and shows broad antitumor effect on many types of cancer. In the present study, we combined EGFRvIII-targeted CAR-T cells with poly I:C treatment and evaluated the synergic antitumor effect in vitro and in immunocompetent mice bearing subcutaneous colon or orthotopic breast cancer xenografts. Poly I:C significantly promoted more IL-2 and IFN γ production as well as higher lytic activity of CAR-T cells. Upon systemic administration in vivo, CAR-T cells suppressed tumor growth obviously and poly I:C significantly enhanced the suppression. Further study showed that poly I:C exerts antitumor effect partially dependent on CD8 T cells and type I IFN signaling. In addition, poly I:C decreased MDSC quantity in peripheral blood and spleen and attenuated the immunosuppressive activity of MDSC on T cell proliferation and CAR-T cytolytic function. Depletion of MDSC with anti-Gr1 Ab further increased the antitumor effect of CAR-T cells plus poly I:C treatment. In conclusion, CAR-T treatment combined with intratumoral delivery of poly I:C resulted in synergistic antitumor activity. We thus provide a rationale to translate this immunotherapeutic strategy to solid tumors.
No takes yet. Share an insight, caveat, or question.
Di et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: